These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37415222)

  • 1. Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models.
    Zhang H; Du Y; Qi L; Xiao S; Braun FK; Kogiso M; Huang Y; Huang F; Abdallah A; Suarez M; Karthick S; Ahmed NM; Salsman VS; Baxter PA; Su JM; Brat DJ; Hellenbeck PL; Teo WY; Patel AJ; Li XN
    J Transl Med; 2023 Jul; 21(1):444. PubMed ID: 37415222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
    Liu Z; Zhao X; Mao H; Baxter PA; Huang Y; Yu L; Wadhwa L; Su JM; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Hurwitz RL; Lau CC; Chintagumpala M; Blaney SM; Li XN
    Neuro Oncol; 2013 Sep; 15(9):1173-85. PubMed ID: 23658322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.
    Yu L; Baxter PA; Zhao X; Liu Z; Wadhwa L; Zhang Y; Su JM; Tan X; Yang J; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Blaney SM; Chintagumpala M; Hurwitz RL; Li XN
    Neuro Oncol; 2011 Jan; 13(1):14-27. PubMed ID: 21075780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
    Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF
    mBio; 2018 Sep; 9(5):. PubMed ID: 30228241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

  • 6. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
    Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
    Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma.
    Spencer D; Yu D; Morshed RA; Li G; Pituch KC; Gao DX; Bertolino N; Procissi D; Lesniak MS; Balyasnikova IV
    Theranostics; 2019; 9(7):2071-2083. PubMed ID: 31037157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
    Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
    Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
    Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
    J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors.
    Qi L; Kogiso M; Du Y; Zhang H; Braun FK; Huang Y; Teo WY; Lindsay H; Zhao S; Baxter P; Zhao X; Yu L; Liu Z; Zhang X; Su JM; Adesina A; Yang J; Chintagumpala M; Perlaky L; Tsz-Kwong Man C; Lau CC; Li XN
    Cancer Lett; 2020 Nov; 493():197-206. PubMed ID: 32891713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
    Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
    Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
    [No Abstract]   [Full Text] [Related]  

  • 12. The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.
    Bhat K; Saki M; Vlashi E; Cheng F; Duhachek-Muggy S; Alli C; Yu G; Medina P; He L; Damoiseaux R; Pellegrini M; Zemke NR; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F
    Proc Natl Acad Sci U S A; 2020 May; 117(20):11085-11096. PubMed ID: 32358191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
    Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
    Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.
    Kurokawa C; Iankov ID; Anderson SK; Aderca I; Leontovich AA; Maurer MJ; Oberg AL; Schroeder MA; Giannini C; Greiner SM; Becker MA; Thompson EA; Haluska P; Jentoft ME; Parney IF; Weroha SJ; Jen J; Sarkaria JN; Galanis E
    J Natl Cancer Inst; 2018 Oct; 110(10):1123-1132. PubMed ID: 29788332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence.
    Oudin A; Moreno-Sanchez PM; Baus V; Niclou SP; Golebiewska A
    BMC Cancer; 2024 Jan; 24(1):3. PubMed ID: 38166949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma.
    Xiao J; Liang J; Fan J; Hou P; Li X; Zhang H; Li K; Bu L; Li P; He M; Zhong Y; Guo L; Jia P; Xiao Q; Wu J; Peng H; Li C; Xing F; Guo D
    Cancer Res; 2022 Sep; 82(18):3359-3374. PubMed ID: 35792620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell Membrane-Coated Oncolytic Adenovirus for Targeted Treatment of Glioblastoma.
    Jia X; Wang L; Feng X; Liu W; Wang X; Li F; Liu X; Yu J; Yu B; Yu X
    Nano Lett; 2023 Dec; 23(23):11120-11128. PubMed ID: 38032110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
    Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
    Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
    Mantwill K; Naumann U; Seznec J; Girbinger V; Lage H; Surowiak P; Beier D; Mittelbronn M; Schlegel J; Holm PS
    J Transl Med; 2013 Sep; 11():216. PubMed ID: 24044901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.